Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04464239 · ClinicalTrials.gov registry record · Phase 1
A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healthy Participants
A Phase 1 study, sponsored by Taisho Pharmaceutical R&D.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT04464239: Completed Phase 1 study, sponsored by Taisho Pharmaceutical R&D.
NCT04464239 is a Phase 1 study that has completed, run by Taisho Pharmaceutical R&D. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04464239, a Phase 1 study, has completed, sponsored by Taisho Pharmaceutical R&D.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a study to evaluate the safety, tolerability, and pharmacokinetics of single oral doses of TS-142 compared to placebo and of a single repeated dose compared to placebo in healthy volunteers. This Phase I study is composed of two parts; Part A (Single Ascending Dose) and Part B (Repeated Dose). The study employs a randomized, double-blind, placebo-controlled, parallel group design to evaluate the single and repeat-dose safety and pharmacokinetics of TS-142 in healthy participants.
Interventions
- DRUG TS-142
- DRUG TS-142 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-09-14 |
| Est. Completion | 2021-01-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04464239
The ClinicalTrials.gov registry entry for NCT04464239 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taisho Pharmaceutical R&D, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TS-142 is the first listed.
NCT04464239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04464239 about?
NCT04464239 is a clinical study titled "A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healthy Participants". This is a study to evaluate the safety, tolerability, and pharmacokinetics of single oral doses of TS-142 compared to placebo and of a single repeated dose compared to placebo in healthy volunteers. This Phase I study is composed of two parts; Part A (Single Ascending Dose) and Part B (Repeated Dose...
What is the current status of trial NCT04464239?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2020-09-14. Estimated completion is 2021-01-21.
What interventions are being tested in trial NCT04464239?
The interventions under investigation include: TS-142 (DRUG), TS-142 Placebo (DRUG).
Who is sponsoring clinical trial NCT04464239?
This trial is sponsored by Taisho Pharmaceutical R&D, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.